Company has said it is postponing deployment in Europe following concerns about blood clots in US
The European commission is seeking “urgent clarification” from Johnson & Johnson after the company’s “completely unexpected” announcement that it has decided to delay the deployment of its coronavirus vaccine across Europe following concerns in the US about a small number of blood clots.
The drug company said in a statement on Tuesday it had been “reviewing these cases with European health authorities” and had “made the decision to proactively delay the rollout of our vaccine in Europe”.
